Trial Search Results
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
Open-label, multi-center, multi-national rollover study to allow continued access to tivozanib for subjects who have participated in other tivozanib (monotherapy or combination) protocols. Eligible subjects will continue to receive tivozanib at the same dose and schedule as per the original (parent) protocol. The length of time that a subject must be on the parent protocol before rolling over to this protocol will be dictated by the (original) parent protocol. Subjects will be seen by the investigator every 4 weeks (± 5 days). Adverse events and blood pressure will be recorded. At the beginning of Cycle 1 and at the beginning of every odd-numbered cycle (Cycle 3, Cycle 5, etc), clinical laboratory values will be recorded. CT scans to assess disease will be performed at the end of even-numbered cycles (Cycle 2, Cycle 4, etc).
Stanford is currently not accepting patients for this trial.
AVEO Pharmaceuticals, Inc.
- Drug: Tivozanib + paclitaxel
- Drug: Tivozanib + temsirolimus
- Drug: Tivozanib
- Drug: Tivozanib (AV-951)
- Drug: Tivozanib + capecitabine
- Drug: Tivo
1. The subject must have received tivozanib while enrolled in another protocol, must be
tolerating study drug and must currently display clinical benefit. The length of time
that a subject must be on the parent protocol before rolling over to this protocol
will be dictated by the parent protocol.
2. If female and of childbearing potential, documentation of negative pregnancy test
prior to enrollment.
3. Ability to give written informed consent.
1. > 4 weeks since discontinuation of tivozanib treatment on a previous protocol
2. If female, pregnant or lactating
3. Sexually active male and pre-menopausal female subjects (and their partners) unless
they agree to use adequate contraceptive measures, while on study and for 30 days
after the last dose of study drug. All fertile male and female subjects (and their
partners) must agree to use a highly effective method of contraception. Highly
effective birth control includes (a) IUD plus one barrier method; or (b) 2 barrier
methods. Effective barrier methods are male or female condoms, diaphragms, and
spermicides (creams or gels that contain a chemical to kill sperm). (Note: Oral,
implantable, or injectable contraceptives may be affected by cytochrome P450
interactions, and are not considered effective for this study.)
4. Uncontrolled hypertension: systolic blood pressure > 140 mmHg or diastolic blood
pressure >90 mmHg on 2 or more antihypertensive medications, documented on 2
consecutive measurements taken at least 24 hours apart.
5. Newly identified CNS malignancies or documented progression of CNS metastases;
subjects will be allowed only if the CNS metastases have been adequately treated with
radiotherapy or surgery. For subjects receiving steroid therapy please refer to
Section 6.3 for allowed steroid maintenance therapy.
6. Unhealed wounds (including active peptic ulcers)
7. Serious/active infection or infection requiring parenteral antibiotics
8. Life-threatening illness or organ system dysfunction compromising safety evaluation
9. Psychiatric disorder, altered mental status precluding informed consent or necessary
10. Inability to comply with protocol requirements
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study